FIGURE 2
FROM:
No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan
L Calvet, A Santos, A Valent, M-J Terrier-Lacombe, P Opolon, J-L Merlin, G Aubert, J Morizet, J H M Schellens, J Bénard and G Vassal
BACK TO ARTICLEFigure 2.
Effect of one cycle of CPT-11 27 mg kg-1 day-1 
5. Passage 1 (P1 – sensitive tumour) and passage 8 (P8 – resistant tumour): treatment discontinued in passage 8 (P8). P8P6 and P8P15: resistance verified in vivo at P8P6 (P6=6 passages without treatment after passage 8 with treatment); P8P15 (P15=15 passages without treatment after passage 8 with treatment). Central bars: medians.
